Momenta Pharmaceuticals, Inc. (MNTA)

[ThSeeker]

If you have a long term view. This could be a big winner. It is well positioned to profit from

...But the FDA approval of the first a whole new kind of generic called a biosimilar earlier this year clears the way for a significant potential market for Momenta. Wheeler said the company has one partnership in place with Baxter International (NYSE: BAX) for a generic of the arthritis drug, Humira, the world’s top-selling drug which is expected to generate $14 billion in revenues for drugmaker AbbVie this year. It is also seeking a partner for other biosimilars in development...

Biosimilars are expected to be huge even more so than transition that occurred when generics were first released. Momenta should be a big player in that transition. Considering the big move it already has seen it could take awhile as some of that may already be priced in.
Marc Lichenfeld, Oxford Club/The Street.com/Oxford Income Letter says that he has identified five companies that will give their investors huge returns on/before October 20, 2015. Momenta is one of them.